Jasper Therapeutics (JSPR) Capital Expenditures (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Capital Expenditures of $295000.0 for Q2 2025, up 243.9% year-over-year from $85780.1 in Q2 2024, and up 202.43% quarter-over-quarter from -$288000.0 in Q1 2025.
Jasper Therapeutics (JSPR) Capital Expenditures (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $295000.0 for Q2 2025.
- In Q2 2025, Capital Expenditures rose 243.9% year-over-year to $295000.0; the TTM figure through Dec 2025 stood at $7000.0 (down 98.73% YoY), while the FY2025 annual figure was $7000.0, down 98.73% from the prior year.
- Capital Expenditures for Q2 2025 stood at $295000.0, up from -$288000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.0 million in Q3 2021, with the low at -$385000.0 in Q3 2023.
- The 5-year median for Capital Expenditures is $27500.0 (2022), against an average of $212777.8.
- Peak annual rise in Capital Expenditures reached 265.19% in 2024, while the deepest fall reached 1963.64% in 2024.
- Jasper Therapeutics' Capital Expenditures stood at $711000.0 in 2021, then decreased by 4.64% to $678000.0 in 2022, then declined by 9.29% to $615000.0 in 2023, then sank by 84.39% to $96000.0 in 2024, then jumped by 207.29% to $295000.0 in 2025.
- Business Quant data shows JSPR's Capital Expenditures at $295000.0 in Q2 2025, -$288000.0 in Q1 2025, and $96000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 295,000.00 |
| Jun 30, 2025 | 295,000.00 |
| Mar 31, 2025 | -288,000.00 |
| Mar 31, 2025 | -288,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 636,000.00 |
| Sep 30, 2024 | 636,000.00 |
| Jun 30, 2024 | -205,000.00 |
| Jun 30, 2024 | -205,000.00 |
| Mar 31, 2024 | 25,000.00 |
| Mar 31, 2024 | 25,000.00 |
| Dec 31, 2023 | 615,000.00 |
| Dec 31, 2023 | 615,000.00 |
| Sep 30, 2023 | -385,000.00 |
| Sep 30, 2023 | -385,000.00 |
| Jun 30, 2023 | 11,000.00 |
| Jun 30, 2023 | 11,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Mar 31, 2023 | 26,000.00 |